Analyze the mechanism of action of axitinib/axitinib

Axitinib/Axitinib (Axitinib) is a small molecule tyrosine kinase inhibitor widely used in the treatment of renal cell carcinoma and various other solid tumors. Its main mechanism of action is to interfere with the proliferation of tumor cells and their angiogenesis process by inhibiting a variety of tyrosine kinases that are closely related to tumor growth and metastasis.

The core anti-tumor mechanism of axitinib is to target and inhibit the vascular endothelial growth factor receptor (VEGFR). VEGF is a key factor in promoting the formation of new blood vessels. In order to meet the needs of rapid proliferation, tumor cells usually secrete a large amount of VEGF to promote the formation of blood vessels and ensure adequate supply of oxygen and nutrients. By binding to and inhibiting the activity of VEGFR, axitinib effectively prevents the activation of this signaling pathway, thereby reducing the blood supply of tumors and limiting tumor growth.

In addition to its inhibitory effect onVEGFR, axitinib can also affect several other important tyrosine kinases, including smooth muscle growth factor receptor (PDGFR) and fibroblast growth factor receptor (FGFR). These receptors play important roles in tumor growth, metastasis and microenvironment remodeling. By inhibiting multiple signaling pathways at the same time, axitinib can more comprehensively intervene in the biological behavior of tumors, thereby improving the therapeutic effect.

Clinical studies have confirmed that axitinib can significantly prolong progression-free survival in patients with advanced renal cell carcinoma, making it one of the important choices in first- or second-line treatment options. Many patients often experience improved disease control with axitinib. However, patients also need to be wary of possible side effects when receiving treatment, such as high blood pressure, fatigue, and oral ulcers.

In summary, axitinib exerts its significant anti-tumor effect by inhibiting multiple tyrosine kinases, especiallyVEGFR. By inhibiting angiogenesis and related signaling pathways required by tumors, the drug can effectively control tumor growth and improve treatment effects.

Reference materials:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84137882-e000-47da-bd5b-fa76ab3c76f9##